Medindia LOGIN REGISTER
Medindia
Advertisement

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Pipeline Review, H2 2017

Wednesday, October 11, 2017 Corporate News
Advertisement
NEW YORK, Oct. 11, 2017 /PRNewswire/ --
Advertisement

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Pipeline Review, H2 2017Read the full report: https://www.reportlinker.com/p04368359SummaryCollagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Collagenase-3 (MMP13) is a member of the matrix metalloproteinase (MMP) family of neutral endopeptidases. It plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN, wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification.Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 4 and 1 respectively. Report covers products from therapy areas Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Infectious Disease, Respiratory and Toxicology which include indications Osteoarthritis, Allergic Asthma, Alphavirus Infections, Arthralgia, Arthritis, Chemotherapy Induced Peripheral Neuropathy, Chikungunya Fever, Congestive Heart Failure (Heart Failure), Edema, Myocardial Infarction, Osteoarthritis Pain and Seasonal Allergic Rhinitis.The latest report Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Pipeline Review, H2 2017, outlays comprehensive information on the Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics development with respective active and dormant or discontinued projects.The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.Scope- The report provides a snapshot of the global therapeutic landscape for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)- The report reviews Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities- The report reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects- The report assesses Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type- The report summarizes all the dormant and discontinued pipeline projects- The report reviews latest news and deals related to Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeuticsReasons to buy- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Identify and understand the targeted therapy areas and indications for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)- Identify the use of drugs for target identification and drug repurposing- Identify potential new clients or partners in the target demographic- Develop strategic initiatives by understanding the focus areas of leading companies- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics- Devise corrective measures for pipeline projects by understanding Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) development landscape- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeRead the full report: https://www.reportlinker.com/p04368359 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. https://www.reportlinker.com__________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/collagenase-3-matrix-metalloproteinase-13-or-mmp13-or-ec-3424---pipeline-review-h2-2017-300534805.html

SOURCE Reportlinker

Sponsored Post and Backlink Submission


Latest Press Release on Corporate News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close